We are actively recruiting for the following clinical trials:
Novartis CAIN457P12301—A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial SpondyloArthritis
https://clinicaltrials.gov/ct2/show/NCT04156620?term=CAIN457P12301&draw=2&rank=1
We are participating in the following trials, but recruitment has ended:
Lilly-I4V-MC-JAJA: A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
https://clinicaltrials.gov/ct2/show/NCT03915964?term=Hillary+Norton&rank=1
Horizon HZNP-KRY-202: A Phase 2, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA® (Pegloticase) (MIRROR)
https://clinicaltrials.gov/ct2/show/NCT03635957?term=horizon+mirror&rank=1
If you are interested in participation, please contact our Clinical Research Coordinator for further information:
(505)-908-3807
alundquist@sfrheumatology.com